| Official American thoracic society/centers for disease control and prevention/infectious diseases society of America clinical practice guidelines: treatment of drug-susceptible … P Nahid, SE Dorman, N Alipanah, PM Barry, JL Brozek, A Cattamanchi, ... Clinical infectious diseases 63 (7), e147-e195, 2016 | 1503 | 2016 |
| Advances in the development of new tuberculosis drugs and treatment regimens A Zumla, P Nahid, ST Cole Nature reviews Drug discovery 12 (5), 388-404, 2013 | 1137 | 2013 |
| Latent tuberculosis infection RM Jasmer, P Nahid, PC Hopewell New England Journal of Medicine 347 (23), 1860-1866, 2002 | 737 | 2002 |
| The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis K Dheda, T Gumbo, G Maartens, KE Dooley, R McNerney, M Murray, ... The lancet Respiratory medicine 5 (4), 291-360, 2017 | 696 | 2017 |
| Towards tuberculosis elimination: an action framework for low-incidence countries K Lönnroth, GB Migliori, I Abubakar, L D'Ambrosio, G De Vries, R Diel, ... European Respiratory Journal 45 (4), 928-952, 2015 | 663 | 2015 |
| Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis N Ahmad, SD Ahuja, OW Akkerman, JWC Alffenaar, LF Anderson, ... The Lancet 392 (10150), 821-834, 2018 | 515 | 2018 |
| Treatment of drug-resistant tuberculosis. An official ATS/CDC/ERS/IDSA clinical practice guideline P Nahid, SR Mase, GB Migliori, G Sotgiu, GH Bothamley, JL Brozek, ... American journal of respiratory and critical care medicine 200 (10), e93-e142, 2019 | 424 | 2019 |
| Adherence interventions and outcomes of tuberculosis treatment: A systematic review and meta-analysis of trials and observational studies N Alipanah, L Jarlsberg, C Miller, NN Linh, D Falzon, E Jaramillo, P Nahid PLoS medicine 15 (7), e1002595, 2018 | 402 | 2018 |
| Drug-resistant tuberculosis: time for visionary political leadership I Abubakar, M Zignol, D Falzon, M Raviglione, L Ditiu, S Masham, I Adetifa, ... The Lancet infectious diseases 13 (6), 529-539, 2013 | 363 | 2013 |
| Four-month rifapentine regimens with or without moxifloxacin for tuberculosis SE Dorman, P Nahid, EV Kurbatova, PPJ Phillips, K Bryant, KE Dooley, ... New England Journal of Medicine 384 (18), 1705-1718, 2021 | 343 | 2021 |
| Sputum monitoring during tuberculosis treatment for predicting outcome: systematic review and meta-analysis DJ Horne, SE Royce, L Gooze, M Narita, PC Hopewell, P Nahid, ... The Lancet infectious diseases 10 (6), 387-394, 2010 | 313 | 2010 |
| Advances in the diagnosis and treatment of tuberculosis P Nahid, M Pai, PC Hopewell Proceedings of the American Thoracic Society 3 (1), 103-110, 2006 | 312 | 2006 |
| A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis MZ Imperial, P Nahid, PPJ Phillips, GR Davies, K Fielding, D Hanna, ... Nature medicine 24 (11), 1708-1715, 2018 | 275 | 2018 |
| Performance of purified antigens for serodiagnosis of pulmonary tuberculosis: a meta-analysis KR Steingart, N Dendukuri, M Henry, I Schiller, P Nahid, PC Hopewell, ... Clinical and vaccine immunology 16 (2), 260-276, 2009 | 266 | 2009 |
| Treatment outcomes of patients with HIV and tuberculosis P Nahid, LC Gonzalez, I Rudoy, BC de Jong, A Unger, LM Kawamura, ... American journal of respiratory and critical care medicine 175 (11), 1199-1206, 2007 | 207 | 2007 |
| Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis Z Lan, N Ahmad, P Baghaei, L Barkane, A Benedetti, SK Brode, ... The Lancet Respiratory Medicine 8 (4), 383-394, 2020 | 191 | 2020 |
| Discriminating between latent and active tuberculosis with multiple biomarker responses M Frahm, ND Goswami, K Owzar, E Hecker, A Mosher, E Cadogan, ... Tuberculosis 91 (3), 250-256, 2011 | 174 | 2011 |
| Detection of Mycobacterium tuberculosis peptides in the exosomes of patients with active and latent M. tuberculosis infection using MRM-MS NA Kruh-Garcia, LM Wolfe, LH Chaisson, WO Worodria, P Nahid, ... PloS one 9 (7), e103811, 2014 | 158 | 2014 |
| Clinical characteristics and treatment outcomes of patients with isoniazid-monoresistant tuberculosis A Cattamanchi, RB Dantes, JZ Metcalfe, LG Jarlsberg, J Grinsdale, ... Clinical Infectious Diseases 48 (2), 179-185, 2009 | 149 | 2009 |
| Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the tuberculosis trials consortium SE Dorman, S Goldberg, JE Stout, G Muzanyi, JL Johnson, M Weiner, ... The Journal of infectious diseases 206 (7), 1030-1040, 2012 | 137 | 2012 |
